Answers are grounded in this paper and cite their sources.
Progression (within 2-7 years) and cancer-specific mortality (within 4-9 years) were examined in 94 patients with localised (T0-T2 NXM0) prostatic cancer. The patients received no initial anti-cancer treatment. A significant difference was found according to the initial T category both in progression (T0 focal 1/13, T0 diffuse 9/53, T1-2 13/28) and in cancer-related death (T0 focal 0/13, T0 diffuse 3/53, T1-2 6/28). Progression (G1 4/48, G2 17/42, G3 2/4) and cancer-related deaths (G1 1/48, G2 7/42, G3 1/4) also showed significant differences according to histological differentiation. No difference could be demonstrated according to age.
No takes yet. Share an insight, caveat, or question.
Waaler et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: